Ashley Moody sold Karyopharm Therapeutics Inc (NASDAQ: KPTI)
Ashley Moody (R-FL), a U.S. Senator, has disclosed 1 trade in Karyopharm Therapeutics Inc (KPTI) since 2025, a single sale, worth an estimated $8K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a sale: Ashley Moody sold $1,001 - $15,000 of Karyopharm Therapeutics Inc (NASDAQ: KPTI) on February 20, 2025. Since that trade, KPTI is down -25.03% against the S&P 500 up +21.24%, an outperformance of -46.27%.
Data updated
Ashley Moody's KPTI trades vs the price
KPTI is down -25.03% since Ashley Moody sold on February 20, 2025, versus +21.24% for the S&P 500.
Performance since this trade
All Ashley Moody KPTI trades
Ashley Moody & KPTI trading FAQ
Is it legal for Ashley Moody to trade Karyopharm Therapeutics Inc (KPTI) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Karyopharm Therapeutics Inc (KPTI), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Ashley Moody sell KPTI?
Ashley Moody disclosed a sale of $1,001 - $15,000 of Karyopharm Therapeutics Inc (KPTI) on February 20, 2025, according to public STOCK Act filings.
How has KPTI performed since Ashley Moody's trade?
Since Ashley Moody sold KPTI on February 20, 2025, the stock is down -25.03%, versus +21.24% for the S&P 500 over the same period, an outperformance of -46.27%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional KPTI trades?
Quantellect tracks every disclosed congressional trade in Karyopharm Therapeutics Inc (KPTI) on the Karyopharm Therapeutics Inc congressional trading page, which aggregates filings across all members of Congress.
Ashley Moody's KPTI tradesAll congressional filings for Karyopharm Therapeutics IncAshley Moody's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.